Arcutis Biotherapeutics unveils expert psoriasis recommendations as shares fall below key averages

Traders Union
All News
Companies
Arcutis Biotherapeutics down 3.17% today

Highlights

ARQT trades below key moving averages amid sustained downside across short-, medium-, and long-term technical trends.
Momentum indicators remain bearish and suggest weak buying interest, with the stock lingering near the bottom of its weekly range.
Price is forecast to trade between $19.75 and $21.85 next week, with strong likelihood of continued downward or sideways movement unless support at $20.50 fails.

Persistent downside pressure as price remains under key moving averages

ARQT is trading at $20.79, firmly below the MA-20 ($21.26), MA-50 ($22.56), and MA-200 ($23.53), signaling persistent short-, medium-, and long-term downside pressure. The Ichimoku Kijun at $21.79 now acts as immediate resistance; near-term support is seen at MA-10 ($20.93) and MA-20 ($21.26), while key resistance clusters at the Ichimoku Kijun ($21.79) and MA-50 ($22.56).

Weakening momentum and oversold bias amid extended weekly decline

MACD on D1 and ADX remain negative, showing weak and declining momentum. RSI (42.65), Stoch RSI (strong sell), and CCI (–59.48) all indicate the market leans toward oversold territory, but not yet at extreme levels. BBP reads as oversold, confirming ongoing dominance by sellers. The AO is neutral, offering no countertrend support. ARQT has fallen $0.67 (3.12%) from last week’s close of $21.46, closing the week at the very bottom of its trading range of $20.50 to $22.06. Weekly volatility stands at 7.61%. This reflects a steady decline from the weekly high, with little sign of a rebound. In today’s session, the stock slipped 3.17% amid continued downward momentum.

High downside risk as bearish signals dominate short-term outlook

Looking ahead, the forecasted trading corridor for the coming week is $19.75 to $21.85, which is within a realistic band given the current price and weekly volatility. The likelihood of a further decrease is very high (more than 80%), while an upward move is less likely, reflecting the broad-based bearish signals on D1 and also on W1 (where RSI, ADX, and MACD all signal sell, and MA-50 remains above price). The baseline scenario is for ARQT to trade sideways around current levels. A bullish outcome would require a breakout above MA-20 and the Ichimoku Kijun (above $21.79), while a bearish scenario would see a sustained breach of support at $20.50, opening room toward the lower $19s. This range remains well above the 52-week low ($12.72) but far from the yearly high ($31.77), anchoring current price action in the upper half of the annual range but under pressure.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Previously it was reported that Arcutis Biotherapeutics demonstrated its commitment to innovation in dermatology by participating in the 25th Annual Fall Clinical Dermatology Conference. With recent developments, investors should closely monitor any new partnerships or product milestones, as these could influence the prevailing scenario for Arcutis shares moving forward.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.